Because anti-TNFs are not recommended after a diagnosis of cancer, and because patients with previous cancers are excluded from clinical trials, the data on anti-TNF use in IBD patients with previous cancer are sparse. The gene discussed is TNF; the disease is inflammatory bowel disease.